{
    "references": [
        {
            "bibentry": "Bray, F, Jemal, A, Grey, N, et al. Global cancer transitions according to the Human Development Index (2008–2030): a population-based study. Lancet Oncol 2012; 13: 790–801. PMID: 22658655",
            "process_entry": "True",
            "doi": "10.1016/s1470-2045(12)70211-5",
            "pmid": "22658655",
            "xmlid": "CIT0001"
        },
        {
            "bibentry": "Siegel, RL, Miller, KD, Jemal, A. Cancer statistics, 2017. CA Cancer J Clin 2017; 67: 7–30. PMID: 28055103",
            "process_entry": "True",
            "doi": "10.3322/caac.21387",
            "pmid": "28055103",
            "xmlid": "CIT0002"
        },
        {
            "bibentry": "Vyse, S, Huang, PH. Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer. Signal Transduct Target Ther 2019; 4: 5. PMID: 30854234",
            "process_entry": "True",
            "doi": "10.1038/s41392-019-0038-9",
            "pmid": "30854234",
            "pmcid": "PMC6405763",
            "xmlid": "CIT0003"
        },
        {
            "bibentry": "Chen, L, Fu, W, Zheng, L, et al. Recent progress of small-molecule epidermal growth factor receptor (EGFR) inhibitors against C797S resistance in non-small-cell lung cancer. J Med Chem 2018; 61: 4290–300. PMID: 29136465",
            "process_entry": "True",
            "doi": "10.1021/acs.jmedchem.7b01310",
            "pmid": "29136465",
            "xmlid": "CIT0004"
        },
        {
            "bibentry": "Khandekar, MJ, Willers, H, Piotrowska, Z, et al. Role of epidermal growth factor receptor (EGFR) inhibitors and radiation in the management of brain metastases from EGFR mutant lung cancers. Oncologist 2018; 23: 1054–62. PMID: 29703765",
            "process_entry": "True",
            "doi": "10.1634/theoncologist.2017-0557",
            "pmid": "29703765",
            "pmcid": "PMC6192617",
            "xmlid": "CIT0005"
        },
        {
            "bibentry": "Ravez, S, Castillo-Aguilera, O, Depreux, P, et al. Quinazoline derivatives as anticancer drugs: a patent review (2011–present). Expert Opin Ther Pat 2015; 25: 789–804. PMID: 25910402",
            "process_entry": "True",
            "doi": "10.1517/13543776.2015.1039512",
            "pmid": "25910402",
            "xmlid": "CIT0006"
        },
        {
            "bibentry": "Kavitha, K, Srinivasan, N, Harbabu, Y. Review of quinazolinone scaffold as anticancer agents. World J Pharm Res 2018; 7: 1–21.",
            "process_entry": "True",
            "xmlid": "CIT0007"
        },
        {
            "bibentry": "Metro, G. EGFR targeted therapy for lung cancer: are we almost there? Transl Lung Cancer Res 2018; 7: S142–S5. PMID: 29782570",
            "process_entry": "True",
            "doi": "10.21037/tlcr.2018.03.11",
            "pmid": "29782570",
            "pmcid": "PMC5943235",
            "xmlid": "CIT0008"
        },
        {
            "bibentry": "Rusnak, DW, Lackey, K, Affleck, K, et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Canc Therapeut 2001; 1: 85–94.",
            "process_entry": "True",
            "xmlid": "CIT0009"
        },
        {
            "bibentry": "Kuwano, M, Sonoda, K, Murakami, Y, et al. Overcoming drug resistance to receptor tyrosine kinase inhibitors: learning from lung cancer. Pharmacol Ther 2016; 161: 97–110. PMID: 27000770",
            "process_entry": "True",
            "doi": "10.1016/j.pharmthera.2016.03.002",
            "pmid": "27000770",
            "xmlid": "CIT0010"
        },
        {
            "bibentry": "Jia, Y, Yun, CH, Park, E, et al. Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors. Nature 2016; 534: 129–32. PMID: 27251290",
            "process_entry": "True",
            "doi": "10.1038/nature17960",
            "pmid": "27251290",
            "pmcid": "PMC4929832",
            "xmlid": "CIT0011"
        },
        {
            "bibentry": "Chen, L, Zhang, Y, Liu, J, et al. Novel 4-arylaminoquinazoline derivatives with (E)-propen-1-yl moiety as potent EGFR inhibitors with enhanced antiproliferative activities against tumor cells. Eur J Med Chem 2017; 138: 689–97. PMID: 28711703",
            "process_entry": "True",
            "doi": "10.1016/j.ejmech.2017.06.023",
            "pmid": "28711703",
            "xmlid": "CIT0012"
        },
        {
            "bibentry": "Towles, JK, Clark, RN, Wahlin, MD, et al. Cytochrome P450 3A4 and CYP3A5-catalyzed bioactivation of lapatinib. Drug Metab Dispos 2016; 44: 1584–97. PMID: 27450182",
            "process_entry": "True",
            "doi": "10.1124/dmd.116.070839",
            "pmid": "27450182",
            "pmcid": "PMC5034700",
            "xmlid": "CIT0013"
        },
        {
            "bibentry": "Cataldo, VD, Gibbons, DL, Perez-Soler, R, et al. Treatment of non-small-cell lung cancer with erlotinib or gefitinib. N Engl J Med 2011; 364: 947–55. PMID: 21388312",
            "process_entry": "True",
            "doi": "10.1056/nejmct0807960",
            "pmid": "21388312",
            "xmlid": "CIT0014"
        },
        {
            "bibentry": "Milik, SN, Lasheen, DS, Serya, RAT, et al. How to train your inhibitor: design strategies to overcome resistance to Epidermal Growth Factor Receptor inhibitors. Eur J Med Chem 2017; 142: 131–51. PMID: 28754471",
            "process_entry": "True",
            "doi": "10.1016/j.ejmech.2017.07.023",
            "pmid": "28754471",
            "xmlid": "CIT0015"
        },
        {
            "bibentry": "Zhang, Y, Zhang, Y, Liu, J, et al. Synthesis and in vitro biological evaluation of novel quinazoline derivatives. Bioorg Med Chem Lett 2017; 27: 1584. PMID: 28238614",
            "process_entry": "True",
            "doi": "10.1016/j.bmcl.2017.02.027",
            "pmid": "28238614",
            "xmlid": "CIT0016"
        },
        {
            "bibentry": "Zhang, Y, Chen, L, Xu, H, et al. 6,7-Dimorpholinoalkoxy quinazoline derivatives as potent EGFR inhibitors with enhanced antiproliferative activities against tumor cells. Eur J Med Chem 2018; 147: 77–89. PMID: 29421573",
            "process_entry": "True",
            "doi": "10.1016/j.ejmech.2018.01.090",
            "pmid": "29421573",
            "xmlid": "CIT0017"
        },
        {
            "bibentry": "Zhang Yaling, MS, Xiabing, L, Hou Qiaoli, L, et al. Quinazoline-1-deoxynojirimycin hybrids as high active dual inhibitors of EGFR and α-glucosidase. Bioorg Med Chem Lett 2017; 27: 4309–13. PMID: 28838691",
            "process_entry": "True",
            "doi": "10.1016/j.bmcl.2017.08.035",
            "pmid": "28838691",
            "xmlid": "CIT0018"
        },
        {
            "bibentry": "Zhang, Y, Ma, S, Li, X, et al. Synthesis and antiproliferative activities of novel pyrrolotriazine derivatives. Chin J Org Chem 2018; 38: 3270–7.",
            "process_entry": "True",
            "xmlid": "CIT0019"
        },
        {
            "bibentry": "Kong, LY, Xue, M, Zhang, QC, et al. In vivo and in vitro effects of microRNA-27a on proliferation, migration and invasion of breast cancer cells through targeting of SFRP1 gene via Wnt/beta-catenin signaling pathway. Oncotarget 2017; 8: 15507–19. PMID: 28099945",
            "process_entry": "True",
            "doi": "10.18632/oncotarget.14662",
            "pmid": "28099945",
            "pmcid": "PMC5362502",
            "xmlid": "CIT0020"
        },
        {
            "bibentry": "Head, T, Dau, P, Duffort, S, et al. An enhanced bioluminescence-based Annexin V probe for apoptosis detection in vitro and in vivo. Cell Death Dis 2017; 8: e2826. PMID: 28542141",
            "process_entry": "True",
            "doi": "10.1038/cddis.2017.141",
            "pmid": "28542141",
            "pmcid": "PMC5520691",
            "xmlid": "CIT0021"
        },
        {
            "bibentry": "Yan, W, Wang, X, Dai, Y, et al. Discovery of 3-(5′-Substituted)-benzimidazole-5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1H-indazo les as potent fibroblast growth factor receptor inhibitors: design, synthesis, and biological evaluation. J Med Chem 2016; 59: 6690–708. PMID: 27348537",
            "process_entry": "True",
            "doi": "10.1021/acs.jmedchem.6b00056",
            "pmid": "27348537",
            "xmlid": "CIT0022"
        },
        {
            "bibentry": "Wood, ER, Truesdale, AT, McDonald, OB, et al. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res 2004; 64: 6652–9. PMID: 15374980",
            "process_entry": "True",
            "doi": "10.1158/0008-5472.can-04-1168",
            "pmid": "15374980",
            "xmlid": "CIT0023"
        }
    ],
    "localid": "MED-31530043",
    "doi": "10.1080/14756366.2019.1667341",
    "pmid": "10.1080/14756366.2019.1667341",
    "pmcid": "31530043",
    "curator": "BEE EuropeanPubMedCentralProcessor",
    "source_provider": "Europe PubMed Central",
    "source": "https://www.ebi.ac.uk/europepmc/webservices/rest/31530043/fullTextXML",
    "reference_pointers": [
        [
            {
                "n_rp": 0,
                "xref_id": "CIT0001",
                "rp_string": "1",
                "rp_xpath": "/article/body/sec[1]/p[1]/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),1,116)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 1,
                "xref_id": "CIT0002",
                "rp_string": "2",
                "rp_xpath": "/article/body/sec[1]/p[1]/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),1,116)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 2,
                "xref_id": "CIT0003",
                "rp_string": "3",
                "rp_xpath": "/article/body/sec[1]/p[1]/xref[3]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),118,181)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "Cancer is set to become a major cause of morbidity and mortality, and is a major public health problem worldwide1,2. Among them, lung cancer is the most common malignant disease3, and accounts for more than 1/4 of cancer related deaths, and the 5-year relative survival is currently less than 20%4. As the pathogenesis of cancer continues to clarify, many biological targets including epidermal growth factor receptor (EGFR) have been identified playing a key role in the development of a number of the most lethal cancers, and the activity of EGFR-specific tyrosine kinase inhibitors (TKIs) against such cancers ushered in an era of genotype-directed targeted therapy that fundamentally changed the overall approach to lung cancer5. Many targeted drugs have been developed and used in clinic, for example, gefitinib, erlotinib, lapatinib, and so on6,7. Gefitinib and erlotinib have been referred as the first generation of EGFR-TKIs4,8, and lapatinib was a dual EGFR and human epidermal growth factor receptor-2 (HER-2) inhibitors9. They have been all approved for cancer treatment by the US Food and Drug Administration (FDA). However, these drugs have some limits in clinical usage, such as drug resistance of gefitinib10,11, hepatotoxicity of lapatinib12,13, and erlotinib has similar toxic-effect profiles with gefitinib14. Ever since FDA approval of “Gefitinib” in 2003 and up to the last FDA approved small molecule EGFR kinase inhibitor “Osimertinib” in 2015, finding more efficient EGFR-TKIs are still going on due to the continuous emergence of resistance to the current inhibitors15.",
                "pl_xpath": "/article/body/sec[1]/p[1]"
            },
            {
                "n_rp": 3,
                "xref_id": "CIT0004",
                "rp_string": "4",
                "rp_xpath": "/article/body/sec[1]/p[1]/xref[4]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),118,181)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "Cancer is set to become a major cause of morbidity and mortality, and is a major public health problem worldwide1,2. Among them, lung cancer is the most common malignant disease3, and accounts for more than 1/4 of cancer related deaths, and the 5-year relative survival is currently less than 20%4. As the pathogenesis of cancer continues to clarify, many biological targets including epidermal growth factor receptor (EGFR) have been identified playing a key role in the development of a number of the most lethal cancers, and the activity of EGFR-specific tyrosine kinase inhibitors (TKIs) against such cancers ushered in an era of genotype-directed targeted therapy that fundamentally changed the overall approach to lung cancer5. Many targeted drugs have been developed and used in clinic, for example, gefitinib, erlotinib, lapatinib, and so on6,7. Gefitinib and erlotinib have been referred as the first generation of EGFR-TKIs4,8, and lapatinib was a dual EGFR and human epidermal growth factor receptor-2 (HER-2) inhibitors9. They have been all approved for cancer treatment by the US Food and Drug Administration (FDA). However, these drugs have some limits in clinical usage, such as drug resistance of gefitinib10,11, hepatotoxicity of lapatinib12,13, and erlotinib has similar toxic-effect profiles with gefitinib14. Ever since FDA approval of “Gefitinib” in 2003 and up to the last FDA approved small molecule EGFR kinase inhibitor “Osimertinib” in 2015, finding more efficient EGFR-TKIs are still going on due to the continuous emergence of resistance to the current inhibitors15.",
                "pl_xpath": "/article/body/sec[1]/p[1]"
            }
        ],
        [
            {
                "n_rp": 4,
                "xref_id": "CIT0005",
                "rp_string": "5",
                "rp_xpath": "/article/body/sec[1]/p[1]/xref[5]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),300,434)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 5,
                "xref_id": "CIT0006",
                "rp_string": "6",
                "rp_xpath": "/article/body/sec[1]/p[1]/xref[6]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),735,119)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 6,
                "xref_id": "CIT0007",
                "rp_string": "7",
                "rp_xpath": "/article/body/sec[1]/p[1]/xref[7]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),735,119)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 7,
                "xref_id": "CIT0004",
                "rp_string": "4",
                "rp_xpath": "/article/body/sec[1]/p[1]/xref[8]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),855,179)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "Cancer is set to become a major cause of morbidity and mortality, and is a major public health problem worldwide1,2. Among them, lung cancer is the most common malignant disease3, and accounts for more than 1/4 of cancer related deaths, and the 5-year relative survival is currently less than 20%4. As the pathogenesis of cancer continues to clarify, many biological targets including epidermal growth factor receptor (EGFR) have been identified playing a key role in the development of a number of the most lethal cancers, and the activity of EGFR-specific tyrosine kinase inhibitors (TKIs) against such cancers ushered in an era of genotype-directed targeted therapy that fundamentally changed the overall approach to lung cancer5. Many targeted drugs have been developed and used in clinic, for example, gefitinib, erlotinib, lapatinib, and so on6,7. Gefitinib and erlotinib have been referred as the first generation of EGFR-TKIs4,8, and lapatinib was a dual EGFR and human epidermal growth factor receptor-2 (HER-2) inhibitors9. They have been all approved for cancer treatment by the US Food and Drug Administration (FDA). However, these drugs have some limits in clinical usage, such as drug resistance of gefitinib10,11, hepatotoxicity of lapatinib12,13, and erlotinib has similar toxic-effect profiles with gefitinib14. Ever since FDA approval of “Gefitinib” in 2003 and up to the last FDA approved small molecule EGFR kinase inhibitor “Osimertinib” in 2015, finding more efficient EGFR-TKIs are still going on due to the continuous emergence of resistance to the current inhibitors15.",
                "pl_xpath": "/article/body/sec[1]/p[1]"
            },
            {
                "n_rp": 8,
                "xref_id": "CIT0008",
                "rp_string": "8",
                "rp_xpath": "/article/body/sec[1]/p[1]/xref[9]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),855,179)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "Cancer is set to become a major cause of morbidity and mortality, and is a major public health problem worldwide1,2. Among them, lung cancer is the most common malignant disease3, and accounts for more than 1/4 of cancer related deaths, and the 5-year relative survival is currently less than 20%4. As the pathogenesis of cancer continues to clarify, many biological targets including epidermal growth factor receptor (EGFR) have been identified playing a key role in the development of a number of the most lethal cancers, and the activity of EGFR-specific tyrosine kinase inhibitors (TKIs) against such cancers ushered in an era of genotype-directed targeted therapy that fundamentally changed the overall approach to lung cancer5. Many targeted drugs have been developed and used in clinic, for example, gefitinib, erlotinib, lapatinib, and so on6,7. Gefitinib and erlotinib have been referred as the first generation of EGFR-TKIs4,8, and lapatinib was a dual EGFR and human epidermal growth factor receptor-2 (HER-2) inhibitors9. They have been all approved for cancer treatment by the US Food and Drug Administration (FDA). However, these drugs have some limits in clinical usage, such as drug resistance of gefitinib10,11, hepatotoxicity of lapatinib12,13, and erlotinib has similar toxic-effect profiles with gefitinib14. Ever since FDA approval of “Gefitinib” in 2003 and up to the last FDA approved small molecule EGFR kinase inhibitor “Osimertinib” in 2015, finding more efficient EGFR-TKIs are still going on due to the continuous emergence of resistance to the current inhibitors15.",
                "pl_xpath": "/article/body/sec[1]/p[1]"
            },
            {
                "n_rp": 9,
                "xref_id": "CIT0009",
                "rp_string": "9",
                "rp_xpath": "/article/body/sec[1]/p[1]/xref[10]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),855,179)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "Cancer is set to become a major cause of morbidity and mortality, and is a major public health problem worldwide1,2. Among them, lung cancer is the most common malignant disease3, and accounts for more than 1/4 of cancer related deaths, and the 5-year relative survival is currently less than 20%4. As the pathogenesis of cancer continues to clarify, many biological targets including epidermal growth factor receptor (EGFR) have been identified playing a key role in the development of a number of the most lethal cancers, and the activity of EGFR-specific tyrosine kinase inhibitors (TKIs) against such cancers ushered in an era of genotype-directed targeted therapy that fundamentally changed the overall approach to lung cancer5. Many targeted drugs have been developed and used in clinic, for example, gefitinib, erlotinib, lapatinib, and so on6,7. Gefitinib and erlotinib have been referred as the first generation of EGFR-TKIs4,8, and lapatinib was a dual EGFR and human epidermal growth factor receptor-2 (HER-2) inhibitors9. They have been all approved for cancer treatment by the US Food and Drug Administration (FDA). However, these drugs have some limits in clinical usage, such as drug resistance of gefitinib10,11, hepatotoxicity of lapatinib12,13, and erlotinib has similar toxic-effect profiles with gefitinib14. Ever since FDA approval of “Gefitinib” in 2003 and up to the last FDA approved small molecule EGFR kinase inhibitor “Osimertinib” in 2015, finding more efficient EGFR-TKIs are still going on due to the continuous emergence of resistance to the current inhibitors15.",
                "pl_xpath": "/article/body/sec[1]/p[1]"
            }
        ],
        [
            {
                "n_rp": 10,
                "xref_id": "CIT0010",
                "rp_string": "10",
                "rp_xpath": "/article/body/sec[1]/p[1]/xref[11]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),1130,199)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "Cancer is set to become a major cause of morbidity and mortality, and is a major public health problem worldwide1,2. Among them, lung cancer is the most common malignant disease3, and accounts for more than 1/4 of cancer related deaths, and the 5-year relative survival is currently less than 20%4. As the pathogenesis of cancer continues to clarify, many biological targets including epidermal growth factor receptor (EGFR) have been identified playing a key role in the development of a number of the most lethal cancers, and the activity of EGFR-specific tyrosine kinase inhibitors (TKIs) against such cancers ushered in an era of genotype-directed targeted therapy that fundamentally changed the overall approach to lung cancer5. Many targeted drugs have been developed and used in clinic, for example, gefitinib, erlotinib, lapatinib, and so on6,7. Gefitinib and erlotinib have been referred as the first generation of EGFR-TKIs4,8, and lapatinib was a dual EGFR and human epidermal growth factor receptor-2 (HER-2) inhibitors9. They have been all approved for cancer treatment by the US Food and Drug Administration (FDA). However, these drugs have some limits in clinical usage, such as drug resistance of gefitinib10,11, hepatotoxicity of lapatinib12,13, and erlotinib has similar toxic-effect profiles with gefitinib14. Ever since FDA approval of “Gefitinib” in 2003 and up to the last FDA approved small molecule EGFR kinase inhibitor “Osimertinib” in 2015, finding more efficient EGFR-TKIs are still going on due to the continuous emergence of resistance to the current inhibitors15.",
                "pl_xpath": "/article/body/sec[1]/p[1]"
            },
            {
                "n_rp": 11,
                "xref_id": "CIT0011",
                "rp_string": "11",
                "rp_xpath": "/article/body/sec[1]/p[1]/xref[12]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),1130,199)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "Cancer is set to become a major cause of morbidity and mortality, and is a major public health problem worldwide1,2. Among them, lung cancer is the most common malignant disease3, and accounts for more than 1/4 of cancer related deaths, and the 5-year relative survival is currently less than 20%4. As the pathogenesis of cancer continues to clarify, many biological targets including epidermal growth factor receptor (EGFR) have been identified playing a key role in the development of a number of the most lethal cancers, and the activity of EGFR-specific tyrosine kinase inhibitors (TKIs) against such cancers ushered in an era of genotype-directed targeted therapy that fundamentally changed the overall approach to lung cancer5. Many targeted drugs have been developed and used in clinic, for example, gefitinib, erlotinib, lapatinib, and so on6,7. Gefitinib and erlotinib have been referred as the first generation of EGFR-TKIs4,8, and lapatinib was a dual EGFR and human epidermal growth factor receptor-2 (HER-2) inhibitors9. They have been all approved for cancer treatment by the US Food and Drug Administration (FDA). However, these drugs have some limits in clinical usage, such as drug resistance of gefitinib10,11, hepatotoxicity of lapatinib12,13, and erlotinib has similar toxic-effect profiles with gefitinib14. Ever since FDA approval of “Gefitinib” in 2003 and up to the last FDA approved small molecule EGFR kinase inhibitor “Osimertinib” in 2015, finding more efficient EGFR-TKIs are still going on due to the continuous emergence of resistance to the current inhibitors15.",
                "pl_xpath": "/article/body/sec[1]/p[1]"
            },
            {
                "n_rp": 12,
                "xref_id": "CIT0012",
                "rp_string": "12",
                "rp_xpath": "/article/body/sec[1]/p[1]/xref[13]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),1130,199)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "Cancer is set to become a major cause of morbidity and mortality, and is a major public health problem worldwide1,2. Among them, lung cancer is the most common malignant disease3, and accounts for more than 1/4 of cancer related deaths, and the 5-year relative survival is currently less than 20%4. As the pathogenesis of cancer continues to clarify, many biological targets including epidermal growth factor receptor (EGFR) have been identified playing a key role in the development of a number of the most lethal cancers, and the activity of EGFR-specific tyrosine kinase inhibitors (TKIs) against such cancers ushered in an era of genotype-directed targeted therapy that fundamentally changed the overall approach to lung cancer5. Many targeted drugs have been developed and used in clinic, for example, gefitinib, erlotinib, lapatinib, and so on6,7. Gefitinib and erlotinib have been referred as the first generation of EGFR-TKIs4,8, and lapatinib was a dual EGFR and human epidermal growth factor receptor-2 (HER-2) inhibitors9. They have been all approved for cancer treatment by the US Food and Drug Administration (FDA). However, these drugs have some limits in clinical usage, such as drug resistance of gefitinib10,11, hepatotoxicity of lapatinib12,13, and erlotinib has similar toxic-effect profiles with gefitinib14. Ever since FDA approval of “Gefitinib” in 2003 and up to the last FDA approved small molecule EGFR kinase inhibitor “Osimertinib” in 2015, finding more efficient EGFR-TKIs are still going on due to the continuous emergence of resistance to the current inhibitors15.",
                "pl_xpath": "/article/body/sec[1]/p[1]"
            },
            {
                "n_rp": 13,
                "xref_id": "CIT0013",
                "rp_string": "13",
                "rp_xpath": "/article/body/sec[1]/p[1]/xref[14]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),1130,199)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "Cancer is set to become a major cause of morbidity and mortality, and is a major public health problem worldwide1,2. Among them, lung cancer is the most common malignant disease3, and accounts for more than 1/4 of cancer related deaths, and the 5-year relative survival is currently less than 20%4. As the pathogenesis of cancer continues to clarify, many biological targets including epidermal growth factor receptor (EGFR) have been identified playing a key role in the development of a number of the most lethal cancers, and the activity of EGFR-specific tyrosine kinase inhibitors (TKIs) against such cancers ushered in an era of genotype-directed targeted therapy that fundamentally changed the overall approach to lung cancer5. Many targeted drugs have been developed and used in clinic, for example, gefitinib, erlotinib, lapatinib, and so on6,7. Gefitinib and erlotinib have been referred as the first generation of EGFR-TKIs4,8, and lapatinib was a dual EGFR and human epidermal growth factor receptor-2 (HER-2) inhibitors9. They have been all approved for cancer treatment by the US Food and Drug Administration (FDA). However, these drugs have some limits in clinical usage, such as drug resistance of gefitinib10,11, hepatotoxicity of lapatinib12,13, and erlotinib has similar toxic-effect profiles with gefitinib14. Ever since FDA approval of “Gefitinib” in 2003 and up to the last FDA approved small molecule EGFR kinase inhibitor “Osimertinib” in 2015, finding more efficient EGFR-TKIs are still going on due to the continuous emergence of resistance to the current inhibitors15.",
                "pl_xpath": "/article/body/sec[1]/p[1]"
            },
            {
                "n_rp": 14,
                "xref_id": "CIT0014",
                "rp_string": "14",
                "rp_xpath": "/article/body/sec[1]/p[1]/xref[15]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),1130,199)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "Cancer is set to become a major cause of morbidity and mortality, and is a major public health problem worldwide1,2. Among them, lung cancer is the most common malignant disease3, and accounts for more than 1/4 of cancer related deaths, and the 5-year relative survival is currently less than 20%4. As the pathogenesis of cancer continues to clarify, many biological targets including epidermal growth factor receptor (EGFR) have been identified playing a key role in the development of a number of the most lethal cancers, and the activity of EGFR-specific tyrosine kinase inhibitors (TKIs) against such cancers ushered in an era of genotype-directed targeted therapy that fundamentally changed the overall approach to lung cancer5. Many targeted drugs have been developed and used in clinic, for example, gefitinib, erlotinib, lapatinib, and so on6,7. Gefitinib and erlotinib have been referred as the first generation of EGFR-TKIs4,8, and lapatinib was a dual EGFR and human epidermal growth factor receptor-2 (HER-2) inhibitors9. They have been all approved for cancer treatment by the US Food and Drug Administration (FDA). However, these drugs have some limits in clinical usage, such as drug resistance of gefitinib10,11, hepatotoxicity of lapatinib12,13, and erlotinib has similar toxic-effect profiles with gefitinib14. Ever since FDA approval of “Gefitinib” in 2003 and up to the last FDA approved small molecule EGFR kinase inhibitor “Osimertinib” in 2015, finding more efficient EGFR-TKIs are still going on due to the continuous emergence of resistance to the current inhibitors15.",
                "pl_xpath": "/article/body/sec[1]/p[1]"
            }
        ],
        [
            {
                "n_rp": 15,
                "xref_id": "CIT0015",
                "rp_string": "15",
                "rp_xpath": "/article/body/sec[1]/p[1]/xref[16]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),1330,265)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 16,
                "xref_id": "CIT0012",
                "rp_string": "12",
                "rp_xpath": "/article/body/sec[1]/p[3]/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),1,560)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_xpath": "substring(string(/article/body/sec[1]/p[3]),162,8)",
                "pl_string": "s12,16–1"
            },
            {
                "n_rp": 21,
                "xref_id": "CIT0016",
                "rp_string": "16–19",
                "pl_string": "16–19",
                "rp_xpath": "/article/body/sec[1]/p[3]/xref[2]",
                "pl_xpath": "/article/body/sec[1]/p[3]/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),1,560)",
                "containers_title": [
                    "Introduction"
                ]
            },
            {
                "n_rp": 22,
                "xref_id": "CIT0017",
                "pl_string": "16–19",
                "pl_xpath": "/article/body/sec[1]/p[3]/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),1,560)",
                "containers_title": [
                    "Introduction"
                ]
            },
            {
                "n_rp": 23,
                "xref_id": "CIT0018",
                "pl_string": "16–19",
                "pl_xpath": "/article/body/sec[1]/p[3]/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),1,560)",
                "containers_title": [
                    "Introduction"
                ]
            },
            {
                "n_rp": 24,
                "xref_id": "CIT0019",
                "pl_string": "16–19",
                "pl_xpath": "/article/body/sec[1]/p[3]/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),1,560)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 21,
                "xref_id": "CIT0016",
                "rp_string": "16–19",
                "pl_string": "16–19",
                "rp_xpath": "/article/body/sec[1]/p[3]/xref[2]",
                "pl_xpath": "/article/body/sec[1]/p[3]/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),1,560)",
                "containers_title": [
                    "Introduction"
                ]
            },
            {
                "n_rp": 22,
                "xref_id": "CIT0017",
                "pl_string": "16–19",
                "pl_xpath": "/article/body/sec[1]/p[3]/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),1,560)",
                "containers_title": [
                    "Introduction"
                ]
            },
            {
                "n_rp": 23,
                "xref_id": "CIT0018",
                "pl_string": "16–19",
                "pl_xpath": "/article/body/sec[1]/p[3]/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),1,560)",
                "containers_title": [
                    "Introduction"
                ]
            },
            {
                "n_rp": 24,
                "xref_id": "CIT0019",
                "pl_string": "16–19",
                "pl_xpath": "/article/body/sec[1]/p[3]/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),1,560)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 25,
                "xref_id": "CIT0017",
                "rp_string": "17",
                "rp_xpath": "/article/body/sec[2]/sec[2]/p[1]/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[2]/sec[2]/p[1]),1,230)",
                "containers_title": [
                    "Results and discussion",
                    "Antiproliferative activity of novel quinazoline derivatives in vitro"
                ]
            }
        ],
        [
            {
                "n_rp": 26,
                "xref_id": "CIT0021",
                "rp_string": "21",
                "rp_xpath": "/article/body/sec[2]/sec[3]/p/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[2]/sec[3]/p),1,252)",
                "containers_title": [
                    "Results and discussion",
                    "Effects of compound 6a on cell apoptosis in A549 cells"
                ]
            }
        ],
        [
            {
                "n_rp": 27,
                "xref_id": "CIT0016",
                "rp_string": "16",
                "rp_xpath": "/article/body/sec[2]/sec[6]/p/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[2]/sec[6]/p),201,346)",
                "containers_title": [
                    "Results and discussion",
                    "Molecular modelling"
                ]
            }
        ],
        [
            {
                "n_rp": 28,
                "xref_id": "CIT0016",
                "rp_string": "16",
                "rp_xpath": "/article/body/sec[4]/sec[2]/p/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[4]/sec[2]/p),68,126)",
                "containers_title": [
                    "Experimental section",
                    "Synthesis"
                ]
            }
        ],
        [
            {
                "n_rp": 29,
                "xref_id": "CIT0012",
                "rp_string": "12",
                "rp_xpath": "/article/body/sec[4]/sec[4]/p/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[4]/sec[4]/p),1,197)",
                "containers_title": [
                    "Experimental section",
                    "MTT assay for the antiproliferative activity in vitro"
                ]
            }
        ],
        [
            {
                "n_rp": 30,
                "xref_id": "CIT0016",
                "rp_string": "16",
                "rp_xpath": "/article/body/sec[4]/sec[4]/p/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[4]/sec[4]/p),1,197)",
                "containers_title": [
                    "Experimental section",
                    "MTT assay for the antiproliferative activity in vitro"
                ]
            }
        ],
        [
            {
                "n_rp": 31,
                "xref_id": "CIT0016",
                "rp_string": "16",
                "rp_xpath": "/article/body/sec[4]/sec[7]/p/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[4]/sec[7]/p),114,195)",
                "containers_title": [
                    "Experimental section",
                    "In vitro EGFRwt tyrosine kinase assay"
                ]
            }
        ],
        [
            {
                "n_rp": 32,
                "xref_id": "CIT0022",
                "rp_string": "22",
                "rp_xpath": "/article/body/sec[4]/sec[7]/p/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[4]/sec[7]/p),114,195)",
                "containers_title": [
                    "Experimental section",
                    "In vitro EGFRwt tyrosine kinase assay"
                ]
            }
        ],
        [
            {
                "n_rp": 33,
                "xref_id": "CIT0023",
                "rp_string": "23",
                "rp_xpath": "/article/body/sec[4]/sec[8]/p/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[4]/sec[8]/p),163,135)",
                "containers_title": [
                    "Experimental section",
                    "Molecular docking"
                ]
            }
        ],
        [
            {
                "n_rp": 34,
                "xref_id": "CIT0016",
                "rp_string": "16",
                "rp_xpath": "/article/body/sec[4]/sec[8]/p/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[4]/sec[8]/p),299,88)",
                "containers_title": [
                    "Experimental section",
                    "Molecular docking"
                ]
            }
        ]
    ]
}